In a separate development, Moderna has commenced the Phase 3 clinical study of its Respiratory Syncytial Virus (RSV) vaccine candidate, mRNA-1345, in the older population. In addition, the company has established bilateral and supranational supply agreements in 15 countries across Latin America. It has contracted Zuellig Pharma in the Asia Pacific, Medison Pharma for Central Eastern Europe and Israel, and Adium Pharma in Latin America. Moderna has signed commercial agreements with distributors to supply its Covid-19 vaccine in 45 countries. “These partnerships and the expansion of our global commercial footprint position Moderna to play an important role in providing healthcare security against Covid-19 and future vaccine-preventable diseases.” A presence in Latin America is a key part of our global commercial strategy. Moderna CEO Stéphane Bancel said: “Our new partnership with Adium will help ensure broad access and delivery of our Moderna Covid-19 vaccine to people across Latin America. In Europe, it would enter Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden. In Asia-Pacific, the company would foray into Hong Kong, Malaysia, Singapore, and Taiwan. The move follows Moderna’s recent plans to expand across 10 additional markets, four in the Asia-Pacific region, and six in Europe, this year. The US drugmaker has reached a distribution service agreement with Adium, which covers 18 countries in Latin America, including Brazil, Mexico, Colombia, and Argentina. Moderna has partnered with Latin America-based pharmaceutical company Adium Pharma to support the commercialisation of its Covid-19 vaccine, Spikevax, across the region. Moderna to commercialise Spikevax in Latin America. The company has a commercial footprint in 56 countries worldwide and is planning to expand its presence in 10 additional markets this year
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |